MedicaidPrior AuthLow impact
Beqvez™ intravenous suspension (Revised)
Humana·KY, SC, VA · Hematology, Internal Medicine, Pediatrics·Medicaid
Effective date
Jul 24, 2024
We identified it
Jun 24, 2026
Summary
Humana has revised its prior authorization policy for Beqvez (gene therapy for Hemophilia B), adding a critical note that Pfizer announced in February 2025 it will stop development and commercialization of this drug. The policy maintains strict eligibility criteria for adults with moderate to severe Hemophilia B.
Action Required
Immediately: Billing team should be aware that Beqvez gene therapy is being discontinued by Pfizer as of February 2025. For any current Hemophilia B patients considering this treatment, refer them to Pfizer's medical information line at 800-438-1985 for support. Continue following existing prior authorization requirements for any remaining treatments through the 60-day approval periods.